Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Core Viewpoint - Valneva SE is actively participating in the 26th World Vaccine Congress, showcasing its advancements in vaccine development, particularly for chikungunya, and engaging with partners in the industry [1][5]. Group 1: Company Participation and Events - Valneva will be represented by its CEO Thomas Lingelbach and senior executives at the World Vaccine Congress from March 31 to April 2, 2026 [1]. - On April 1, 2026, Susanne Eder-Lingelbach will present updates on chikungunya vaccine development, focusing on Phase IV and real-world evidence studies [2]. - Valneva's Chief Medical Officer, Dr. Juan Carlos Jaramillo, will participate in a panel discussion on chikungunya and mosquito-borne vaccines on the same day [4]. Group 2: Chikungunya Vaccine Campaign - Valneva and Instituto Butantan have launched a pilot vaccination campaign for the chikungunya vaccine IXCHIQ® in Brazil, with over 12,000 individuals vaccinated to assess the vaccine's effectiveness and safety in real-world conditions [3]. Group 3: Industry Context - Chikungunya virus (CHIKV) is a significant public health concern, with over 3.7 million cases reported in the Americas between 2013 and 2023, and its economic impact is expected to grow due to climate change [6]. - The World Health Organization (WHO) has identified chikungunya as a major public health problem, emphasizing the need for effective vaccines [6]. Group 4: Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7]. - The company has a strong track record in advancing vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8]. - Revenues from its commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease and Shigella, among others [9].